SYRE
Bearish signalScored 2026-10-07 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Spyre Therapeutics, Inc.
- Nom
- Spyre Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $8.3B
- Employés
- 125
- PDG
- Cameron Turtle
- Site web
- https://www.spyre.com
- Marché
- ABVXACRSAGMBANABARDXIFRX
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 30 000 titres (~2 632 500,00 $ US)
- Insiders
- Turtle Cameron
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,134,726
Avg sell (VWAP, 90d window) $91.52 vs last close $80.85 (-11.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$4,134,726 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Liquid $122,850,067/day · 20d vol
- Last synced
-
2026-10-07 21:10:56
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | Burrows Scott L | Sell · S · 10b5-1 | 229 | $93.57 | $21,428 | Form 4 |
| 2026-10-01 | King-Jones Heidy | Sell · S · 10b5-1 | 2,600 | $93.46 | $242,996 | Form 4 |
| 2026-10-01 | Turtle Cameron | Sell · S · 10b5-1 | 100 | $93.91 | $9,391 | Form 4 |
| 2026-09-30 | Burrows Scott L | Sell · S · 10b5-1 | 17,500 | $89.89 | $1,573,075 | Form 4 |
| 2026-09-02 | Burrows Scott L | Sell · S · 10b5-1 | 18,232 | $89.35 | $1,629,029 | Form 4 |
| 2026-09-02 | King-Jones Heidy | Sell · S · 10b5-1 | 400 | $90.00 | $36,000 | Form 4 |
| 2026-09-01 | Burrows Scott L | Sell · S · 10b5-1 | 200 | $89.04 | $17,808 | Form 4 |
| 2026-09-01 | King-Jones Heidy | Sell · S · 10b5-1 | 400 | $89.38 | $35,752 | Form 4 |
| 2026-09-01 | Turtle Cameron | Sell · S · 10b5-1 | 400 | $89.07 | $35,628 | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | Sell · S · 10b5-1 | 5,000 | $104.47 | $522,350 | Form 4 |
| 2026-08-03 | Burrows Scott L | Sell · S · 10b5-1 | 100 | $97.10 | $9,710 | Form 4 |
| 2026-08-03 | Turtle Cameron | Sell · S · 10b5-1 | 16 | $97.46 | $1,559 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-07 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
SYRE presents a deeply unfavorable risk/reward profile: despite adequate liquidity, the company generates zero revenue, persistent operating losses, and negative returns on all capital metrics.
The first sentence of the analysis written for SYRE on 2026-10-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $4.1M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $4.1M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 13.25 · operating margin 0.0%
Suggested stop 61.92, nearest stored support minus 0.5 ATR(23.4% under the last close). Reward/risk to the next stored resistance is 0.39. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | 0.0% | -14510.6% | -3604.6% | -350.4% | |
| Ebitda Margin | 0.0% | 0.0% | -14401.8% | -3520.3% | -342.0% | |
| Operating Profit Margin | 0.0% | 0.0% | -27348.0% | -3640.2% | -350.3% | |
| Pretax Profit Margin | 0.0% | 0.0% | -38241.1% | -3604.6% | -350.4% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -38238.1% | -3598.8% | -351.1% | |
| Net Profit Margin | 0.0% | 0.0% | -38238.1% | -3598.8% | -351.1% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -10709.1% | -3598.8% | -351.1% | |
| Current Ratio | 13.253 | 11.256 | 10.680 | 4.248 | 4.909 | |
| Quick Ratio | 13.253 | 11.256 | 10.680 | 4.248 | 4.909 | |
| Solvency Ratio | -2.322 | -2.294 | -2.140 | -3.928 | -2.472 | |
| Cash Ratio | 1.461 | 1.654 | 5.907 | 2.379 | 0.752 | |
| Price To Earnings Ratio | -16.545 | -7.321 | -0.466 | -0.453 | -4.746 | |
| Price To Earnings Growth Ratio | 0.438 | 0.079 | -0.005 | 0.708 | 0.140 | |
| Forward Price To Earnings Growth Ratio | 0.438 | 0.079 | -0.005 | 0.708 | 0.140 | |
| Price To Earnings Diluted Ratio | -16.545 | -7.321 | -0.466 | -0.453 | -4.746 | |
| Price To Earnings Diluted Growth Ratio | 0.438 | 0.079 | -0.005 | 0.708 | 0.140 | |
| Price To Book Ratio | 2.934 | 2.114 | 0.807 | 0.754 | 3.720 | |
| Price To Sales Ratio | 0.000 | 0.000 | 167.522 | 16.284 | 16.665 | |
| Price To Free Cash Flow Ratio | -12.399 | -6.955 | -1.486 | -0.473 | -5.752 | |
| Price To Operating Cash Flow Ratio | -12.399 | -6.955 | -1.486 | -0.473 | -5.814 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.065 | 0.046 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.092 | 0.060 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.084 | 0.057 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.087 | 1.175 | 1.858 | 1.414 | 1.310 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.005 | 0.037 | 0.177 | |
| Operating Cash Flow Ratio | -2.884 | -2.912 | -3.124 | -5.468 | -2.667 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -112.765 | -34.411 | -2.867 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.011 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -17.313 | -10.616 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | -2,109.053 | -93.745 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | -2,109.053 | -93.745 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -9.605 | -4.834 | 0.317 | -0.094 | -4.716 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-60.0% |
| Ebit Margin | 0.0% | 0.0% | ▲3693.1% |
| Ebitda Margin | 0.0% | 0.0% | ▲3652.8% |
| Operating Profit Margin | 0.0% | 0.0% | ▲6267.7% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲8439.2% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲8437.6% |
| Net Profit Margin | 0.0% | 0.0% | ▲8437.6% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲2931.8% |
| Current Ratio | 13.254 | ▲1.998 | ▲4.384 |
| Quick Ratio | 13.254 | ▲1.998 | ▲4.384 |
| Solvency Ratio | -2.322 | ▼-0.028 | ▲0.309 |
| Cash Ratio | 1.461 | ▼-0.193 | ▼-0.970 |
| Price To Earnings Ratio | -16.546 | ▼-9.225 | ▼-10.639 |
| Price To Earnings Growth Ratio | 0.439 | ▲0.360 | ▲0.167 |
| Forward Price To Earnings Growth Ratio | 0.439 | ▲0.360 | ▲0.167 |
| Price To Earnings Diluted Ratio | -16.546 | ▼-9.225 | ▼-10.639 |
| Price To Earnings Diluted Growth Ratio | 0.439 | ▲0.360 | ▲0.167 |
| Price To Book Ratio | 2.934 | ▲0.820 | ▲0.868 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-40.094 |
| Price To Free Cash Flow Ratio | -12.399 | ▼-5.444 | ▼-6.986 |
| Price To Operating Cash Flow Ratio | -12.399 | ▼-5.444 | ▼-6.973 |
| Debt To Assets Ratio | 0.000 | 0.000 | ▼-0.022 |
| Debt To Equity Ratio | 0.000 | 0.000 | ▼-0.030 |
| Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.028 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.087 | ▼-0.088 | ▼-0.281 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.044 |
| Operating Cash Flow Ratio | -2.884 | ▲0.028 | ▲0.527 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲30.009 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.002 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲5.586 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲440.560 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲440.560 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -9.605 | ▼-4.770 | ▼-5.818 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.10B | $1.09B | $148.4M | $37.9M | $312.3M | |
| Enterprise value | $2.01B | $1.01B | -$40.5M | $7.7M | $302.2M | |
| EV / Sales | 0.00x | 0.00x | -45.67x | 3.30x | 16.13x | |
| EV / Op. cash flow | -11.89x | -6.39x | 0.41x | -0.10x | -5.63x | |
| EV / Free cash flow | -11.89x | -6.39x | 0.41x | -0.10x | -5.57x | |
| EV / EBITDA | -9.61x | -4.83x | 0.32x | -0.09x | -4.72x | |
| Net debt / EBITDA | 0.41x | 0.43x | 1.48x | 0.37x | 0.16x | |
| Current ratio | 13.25x | 11.26x | 10.68x | 4.25x | 4.91x | |
| Income quality | 1.09x | 0.76x | 0.29x | 0.96x | 0.82x | |
| Graham net-net | $11 | $11 | $26 | $10 | $26 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 99.8% | 100.2% | |
| Interest burden | 70.7% | 100.0% | 263.5% | 100.0% | 100.0% | |
| Working capital | $719.1M | $554.4M | $309.6M | $47.6M | $78.7M | |
| Invested capital | $719.1M | $554.4M | $309.6M | $54.3M | $87.1M | |
| Return on assets | -20.0% | -34.2% | -99.1% | -117.8% | -59.9% | |
| Operating ROA | -30.2% | -43.9% | -117.3% | -93.6% | -48.4% | |
| Return on tangible assets | -20.0% | -34.2% | -99.1% | -117.8% | -59.9% | |
| Return on equity | -21.7% | -40.2% | -184.1% | -166.6% | -78.4% | |
| Return on invested capital | -29.1% | -37.6% | -78.2% | -148.2% | -72.8% | |
| Return on capital employed | -29.1% | -37.6% | -78.2% | -150.1% | -73.1% | |
| Earnings yield | -7.4% | -19.0% | -228.3% | -221.0% | -21.1% | |
| Free cash flow yield | -8.1% | -14.4% | -67.3% | -211.4% | -17.4% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | -0.0% | -1.1% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 2.4% | 36.4% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 1.6% | 3.1% | |
| SG&A / Sales | 0.0% | 0.0% | 4508.6% | 1225.0% | 145.8% | |
| R&D / Sales | 0.0% | 0.0% | 10102.0% | 2515.2% | 304.5% | |
| Stock comp / Sales | 0.0% | 0.0% | 2897.9% | 305.3% | 42.9% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 59d | 16d | |
| Days payables outstanding | 19d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 59d | 16d | |
| Cash conversion cycle | -19d | 0d | 0d | 59d | 16d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company''s common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.
- 2026-10-05 Spyre Therapeutics Announces Proposed Public Offering of its Common Stock WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional 15% of the shares of common stock offered in the public offering under the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 2026-10-04 Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale What happened Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary Heidy King-Jones sold 28,933 shares on 2026-10-01. The Form 4 shows five sale blocks at weighted-average prices from $89.24 to $93.46 per share, totaling about $2.63 million. It also shows a separate 28,933-share option exercise at $14.5 per share, and the filing
- 2026-10-02 Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre''s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 21,424 shares of common stock of Spyre and 6,604 restricted stock units (“RSUs”) to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on October 1, 2026 and were material to each employee''s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-10-02 Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – Should You Buy? Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)''s stock price gapped up prior to trading on Wednesday. The stock had previously closed at $84.72, but opened at $88.64. Spyre Therapeutics shares last traded at $90.4130, with a volume of 259,548 shares trading hands. Analysts Set New Price Targets SYRE has been the subject of a
- 2026-09-28 Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison Spyre Therapeutics (NASDAQ: SYRE - Get Free Report) and Gain Therapeutics (NASDAQ: GANX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Valuation and Earnings This table compares Spyre Therapeutics
- 2026-09-15 California State Teachers Retirement System Buys 5,683,670 Shares of Spyre Therapeutics, Inc. $SYRE California State Teachers Retirement System grew its stake in shares of Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 9,594.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,742,912 shares of the company''s stock after acquiring an additional 5,683,670 shares during the
- 2026-09-14 11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ: SYRE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,250 shares of the company''s stock, valued at approximately $999,000. Other hedge funds have
- 2026-09-09 Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript
- 2026-09-09 Spyre''s Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study SYRE''s SPY003 posts positive phase II UC data, strengthening Spyre''s multi-mechanism IBD strategy.